The all-antibody–based doublet comprising teclistamab-cqyv (Tecvayli) and daratumumab (Darzalex) produced deep responses, high minimal residual disease (MRD) negativity rates, and was well-tolerated when administered as frontline treatment to…
Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM
